ST. PAUL, Minn.--(BUSINESS WIRE)--May 2, 2006--St. Jude Medical, Inc. (NYSE:STJ - News) today announced U.S. Food and Drug Administration (FDA) approval, receipt of European CE Mark clearance and market launch of the QuickSite® XL bipolar, left-heart lead to treat heart failure patients.
